StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/3013% below fair value
$13.32−1.01 (-7.05%)

Close on Nov 19, 2026Market cap $724.17MP/E –Yield –

Beta Bionics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Beta Bionics's free cash flow for the twelve months ending Sep 30, 2026 was -$65.96M. For fiscal 2025 it was -$56.22M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$56.22M–
FY2024Dec 31, 2024-$51.67M–
FY2023Dec 31, 2023-$32.85M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$14.56M–
Q2 FY2026Jun 30, 2026-$15.66M–
Q1 FY2026Mar 31, 2026-$25.21M–
Q4 FY2025Dec 31, 2025-$10.53M–
Q3 FY2025Sep 30, 2025-$10.01M–
Q2 FY2025Jun 30, 2025-$15.37M–
Q1 FY2025Mar 31, 2025-$20.31M–
Q4 FY2024Dec 31, 2024-$14.84M–
Q3 FY2024Sep 30, 2024-$11.53M–
Q2 FY2024Jun 30, 2024-$12.74M–
Q1 FY2024Mar 31, 2024-$12.55M–

More Beta Bionics figures

See a number that looks wrong?